|
Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP). |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Esperas Pharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche Canada (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Jennifer Elisabeth Friedmann |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genzyme |
|
|
No Relationships to Disclose |
|
|
Research Funding - Celldex (Inst); GlaxoSmithKline (Inst) |
|
|
Honoraria - Eisai; Novartis |
Consulting or Advisory Role - Eisai; NanoString Technologies; Novartis; Pfizer |
Speakers' Bureau - Eisai; Roche |
Research Funding - Abbvie; Celgene; Novartis; Puma Biotechnology; Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Janssen; Merck; Roche |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Folia Biotech; Folia Biotech; Merck; Prevent Products, Inc.; Prevent Products, Inc. |
Patents, Royalties, Other Intellectual Property - NIH |